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Introduction: Personalized medicine is the holy grail of medicine. The EULAR recommendations for the
management of rheumatoid arthritis (RA) support differential treatment between patients with baseline
characteristics suggestive of a non-poor prognosis (non-PP) or poor prognosis (PP) (presence of autoantibodies, a
high inflammatory activity and damage on radiographs). We aimed to determine which prognostic risk groups
benefit more from initial monotherapy or initial combination therapy.
Methods: 508 patients were randomized to initial monotherapy (iMono) or initial combination therapy (iCombo).
Disease outcomes of iMono and iCombo were compared within non-PP or PP groups as determined on baseline
characteristics
Results: PP patients treated with iCombo after three months more often achieved ACR20 (70% vs 38%, P <0.001),
ACR50 (48% vs 13%, P <0.001) and ACR70 response (24% vs 4%, P <0.001) than those treated with iMono, and had
more improvement in HAQ (median decrease 0.75 vs 0.38, P <0.001). After 1 year, differences in ACR20 response
and DAS-remission remained; PP patients treated with iCombo (vs iMono) had less radiographic progression
(median 0.0 vs 1.5, P =0.001).
Non-PP patients treated with iCombo after three months more often achieved an ACR response (ACR20: 71%
versus 44%, P <0.001; ACR50: 49% vs 13%, P <0.001; ACR70: 17% vs 3%, P =0.001) than with iMono, and functional
ability showed greater improvement (median decrease in HAQ 0.63 vs 0.38, P <0.001). After 1 year, differences in
ACR20 and ACR50 response remained; radiographic progression was comparable between the groups.
Non-PP and PP patients responded equally well to iCombo in terms of improvement of functional ability, with
similar toxicity.
Conclusions: Since PP and non-PP patients benefit equally from iCombo through earlier clinical response and
functional improvement than with iMono, we conclude that personalized medicine as suggested in the guidelines
is not yet feasible. The choice of treatment strategy should depend more on rapid relief of symptoms than on
prognostic factors.
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1Department of Rheumatology, Leiden University Medical Center, PO BOX
9600, 2300 RC Leiden, the Netherlands
Full list of author information is available at the end of the article
© 2014 Markusse et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Markusse et al. Arthritis Research & Therapy 2014, 16:430 Page 2 of 9
http://arthritis-research.com/content/16/5/430Introduction
Clinical trials have shown that on a group level, patients
with early rheumatoid arthritis (RA) treated with initial
combination therapy achieve earlier decrease in disease
activity, improvement in functional ability and less radio-
graphic joint damage progression than patients treated
with initial monotherapy [1-7]. However, for individual pa-
tients there is a need for individualized treatment. The
2010 European League Against Rheumatism (EULAR)
recommendations stated that ‘patients with a favourable
prognosis very often respond similarly to low-intensity
monotherapy or intensive medication strategiesʼ, suggest-
ing that for patients with a poor prognosis this might be
different [8]. It was also formulated that ‘occasional pa-
tients with a particular need for rapid, highly effective
intervention, may benefit from starting a biological agent
plus methotrexate as a viable and useful optionʼ, which
was built on the idea that ‘patients with poor prognostic
factors have more to gainʼ [8]. This opinion was aban-
doned in the updated 2013 recommendations, but these
also state that ‘risk stratification is an important aspect of
the therapeutic approach to RAʼ [9], detailing that after
failure to achieve low disease activity on methotrexate
monotherapy, ‘in patients with a low risk of poor RA out-
come, another conventional synthetic disease-modifying
antirheumatic drug (DMARD) strategy would be pre-
ferred, while in patients with a high risk, the addition of a
biologic DMARD would be preferredʼ [9]. Hence, the
recommendations encourage rheumatologists to use risk
stratification in daily practice and to implement a person-
alized approach in the treatment of patients with RA.
In this post hoc analysis of the BeSt study, we investi-
gated whether patients with poor or non-poor prognos-
tic factors (based on previously developed prediction
models [10-13]) respond differently to initial monother-
apy, and whether patients with a poor or non-poor prog-
nosis respond differently to initial combination therapy,
as suggested by the EULAR recommendations. Further-
more, we studied the efficacy of a second conventional
synthetic DMARD in patients with a low risk of poor
RA outcome who failed on the first.
Methods
Patients
In the BeSt (Dutch acronym for treatment strategies)
study, 508 patients with early RA fulfilling the 1987 criteria
[14] were included and randomized to one of four treat-
ment strategies: (1) sequential monotherapy, (2) step-up
combination therapy, (3) initial combination with metho-
trexate (MTX), sulfasalazine (SSA) and a tapered high dose
of prednisone, (4) initial combination with MTX and
infliximab. For this analysis, groups 1 and 2 (both starting
with MTX monotherapy) were combined, because they
had very similar disease outcomes during the first year offollow up [7], as also group 3 and 4 (both starting with
combination therapy as shown in Figure 1). Three-
monthly clinical assessments included the disease activity
score (DAS) and the health assessment questionnaire
(HAQ) to measure functional ability. Radiographs of hands
and feet were collected yearly and assessed by two inde-
pendent readers, in random order and blinded to patient
identity, using the Sharp van der Heijde score (SHS) [15].
In all groups, the treat-to-target strategy required
treatment adjustments when DAS was >2.4 (treatment
steps are depicted in Figure 1). Dose tapering occurred if
DAS was ≤2.4 for ≥6 months and the last antirheumatic
drug was discontinued if DAS was <1.6 for ≥6 months
(for details see previous publications [6,7]). The ethics
committees of all participating centers approved the
study protocol (listed in Acknowledgements) and pa-
tients gave written informed consent.
Stratification for prognosis
Because there is no unambiguous method to determine
which patients are ‘poor prognosis patients’ (PP patients),
we used two different methods and tested both. The first
method defined poor prognosis as presence of at least
three out of four baseline disease characteristics, based on
determinants used in prediction models [10-13]: DAS ≥3.7,
swollen joint count (SJC) ≥10, erosions ≥4 and both
rheumatoid factor (RF)-positive and anti-citrullinated pep-
tide autoantibodies (ACPA)-positive. Consequently, non-
poor prognosis patients (non-PP patients) were defined as
having ≤2 features of poor prognosis. The latter category
represents a heterogeneous group, including patients in a
range from an evident favourable prognosis to patients
with a moderate prognosis. The results of this stratification
method are discussed in Results.
The second method was to classify all patients accord-
ing to the matrix risk model for rapid radiographic pro-
gression (RRP, defined as an increase of ≥5 points in
SHS during the first year) designed in the BeSt study
[10]. This model estimates the risk of RRP with three
baseline characteristics: the number of erosions, C-
reactive protein and RF and ACPA status. Using the
matrix for initial monotherapy, a cutoff of 50% risk for
RRP was used to distinguish PP and non-PP patients.
The results of this stratification method are shown in
Additional files 1, 2, 3 and 4, and are not discussed in
Results.
Endpoints
Percentages of PP and non-PP patients treated with initial
combination therapy who could discontinue prednisone
or infliximab during the first year, because of a good re-
sponse, were compared. Percentages of PP and non-PP pa-
tients receiving initial monotherapy who failed to achieve
DAS ≤2.4 on MTX monotherapy after six months were
Figure 1 Treatment steps per strategy. CSA, ciclosporine A 2.5 mg/kg/day; MTX, methotrexate; IFX: infliximab; pred: prednisone 7.5 mg/day
unless indicated otherwise; SSA, sulphasalazine 2000 mg/day.
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months after the introduction of a second conventional
synthetic DMARD. To assess the outcomes of initial treat-
ment options in non-PP and PP patients, we compared
the clinical response (percentage of patients achieving
DAS remission, defined as DAS <1.6 [16]; American Col-
lege of Rheumatology (ACR)20, ACR50 and ACR70 re-
sponse [17]; median decrease in HAQ) after three months
and after one year. To define which patients benefit the
most from initial combination therapy, the steepness of
the slope of decrease in HAQ was compared between PP
and non-PP patients. This was also tested for PP and non-
PP patients receiving initial monotherapy. Radiographic
progression (increase in SHS) at year one and the percent-
age of patients with RRP were compared between the
groups. Adverse events (AE) and serious adverse events
(SAE) were compared between PP and non-PP patients
treated with initial combination therapy.
Statistical analysis
The independent t-test, Mann-Whitney U-test, Fischer’s
exact test, chi square (χ2) test, logistic regression analysis
and linear regression analysis were used, depending on di-
chotomy or continuity and distributions of determinants
and outcomes. For radiographic progression as the out-
come, Poisson regression was used to take into account
the non-normal distribution of radiographic progression,
with an excess of zeros. To compare the decrease in HAQ
between PP and non-PP patients, the mean difference wascalculated and tested with the independent t-test. A P-
value <0.05 was considered statistically significant.
Results
Here, the results of defining PP patients by the presence
of ≥3 of 4 poor prognostic factors (and consequently the
non-PP patients by the presence of ≤2 of these factors)
are discussed. The results of prognosis stratification ac-
cording to the RRP matrix model of Visser et al. [10] are
shown in Additional files 1, 2, 3 and 4.
Of 508 patients, 417 (82%) were classified as having a
poor or a non-poor prognosis based on the available data.
Of the 192/417 patients (46%) with PP, 100 (52%) had
been randomized to initial monotherapy and 92 (48%)
to initial combination therapy. Of 225/417 patients (54%)
with a non-PP, 100 (44%) were treated with initial mono-
therapy and 125 (56%) with initial combination therapy.
Baseline characteristics per treatment strategy and
prognosis category are shown in Table 1. Characteristics
were similar among the randomization arms, but princi-
pally as a consequence of the stratification for prognosis,
there were differences between prognosis categories. Al-
though age was not a determinant to classify prognosis,
patients with a poor prognosis were found to be older
than patients with a non-poor prognosis.
Treatment response
Of 92 PP patients who received initial combination ther-
apy, 47 (51%) could discontinue prednisone or infliximab
Table 1 Baseline characteristics of 417 patients classified as having a poor prognosis or a non-poor prognosis
Poor prognosis patients Non-poor prognosis patients
Initial mono Initial combo Initial mono Initial combo P-value
(n =100) (n =92) (n =100) (n =125)
Age, years, mean ± SD 56 ± 13 58 ± 15 53 ± 13 51 ± 13 0.002
Gender, n (%) female 68 (68) 60 (65) 72 (72) 78 (62) 0.481
Treatment strategy, n (%) <0.001
1. Sequential monotherapy (MTX) 51 (51) 0 54 (54) 0
2. Step-up therapy (MTX) 49 (49) 0 46 (46) 0
3. MTX, SSA and prednisone 0 43 (47) 0 61 (49)
4. MTX and infliximab 0 49 (53) 0 64 (51)
Disease activity score, mean ± SD 4.8 ± 0.7 4.5 ± 0.6 4.3 ± 0.9 4.1 ± 0.9 <0.001
Swollen joint count, median (IQR) 17 (11–22) 15 (12–18) 11 (8–16) 11 (8–17) <0.001
Tender joint count, median (IQR) 14 (11–19) 13 (10–19) 13 (8–16) 12 (8–17) <0.001
ESR, mean ± SD 51 ± 30 44 ± 29 37 ± 25 35 ± 24 <0.001
VAS gh, mean ± SD 61 ± 21 57 ± 22 60 ± 23 60 ± 21 0.754
HAQ, mean ± SD 1.4 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 1.3 ± 0.7 0.633
RF-positive, n (%) 85 (85) 79 (86) 49 (49) 54 (43) <0.001
ACPA-positive, n (%) 87 (89) 76 (84) 40 (41) 49 (40) <0.001
Erosive disease, n (%) 79 (81) 78 (85) 62 (63) 74 (60) <0.001
ACPA, anti-citrullinated autoantibodies; Erosive disease, defined as the presence of >0.5 erosion on radiographs of hands and feet; ESR, erythrocyte sedimentation rate;
HAQ, health assessment questionnaire (0 to 3 scale); Initial combo, initial combination therapy with either prednisone or infliximab; Initial mono, initial monotherapy with
methotrexate; MTX, methotrexate; Non-poor prognosis patients (presence of ≤2 of 4 poor prognostic factors); Poor prognosis patients (presence of ≥3 of 4 poor
prognostic factors); RF, IgM rheumatoid factor; SSA, sulphasalazine; VAS gh, visual analogue scale (0 to 100 millimeter scale) of general health.
Figure 2 Mean difference in health assessment questionnaire
(HAQ) score in patients treated with initial combination
therapy or initial monotherapy when prognosis was defined by
prognostic factors. HAQ scale 0 to 3; Non-PP, non-poor prognosis;
PP, poor prognosis.
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consecutive months. Similarly, of 125 non-PP patients
treated with initial combination therapy, 70 (56%) could
discontinue prednisone or infliximab (P =0.674).
After six months, 55/100 PP patients (55%) and 33/100
non-PP patients (33%) who had been allocated to initial
monotherapy had not achieved a DAS ≤2.4 on MTX
monotherapy despite a dose increase at three months from
15 mg/week to 25 mg/week (P =0.007). Three months
later, 39/55 (72%) PP patients and 25/33 non-PP patients
(76%) had also failed to achieve DAS ≤2.4 after switching
to or adding SSA (P =0.364) and one non-PP patient (3%)
was treated outside of protocol.
Clinical outcomes after three months follow up
Significantly more PP patients who were treated with ini-
tial combination therapy fulfilled the ACR20 response cri-
teria after three months than those treated with initial
monotherapy (70% versus 38%, P <0.001). This was the
same for ACR50 response (48% versus 13%, P <0.001),
ACR70 response (24% versus 4%, P <0.001) and for DAS
remission (17% versus 5%, P =0.016). Patients treated with
combination therapy had a significantly greater improve-
ment in functional ability (median decrease in HAQ 0.75
versus 0.38, P <0.001). This resulted in a mean HAQ score
at 3 months of 0.60 in patients treated with initial com-
bination therapy compared to a mean HAQ score of1.08 in patients treated with initial monotherapy (see
also Figure 2).
Non-PP patients treated with initial combination ther-
apy more often met the ACR response criteria at three
months compared to those treated with initial monother-
apy; ACR20 (71% versus 44%, P <0.001), ACR50 (49% ver-
sus 13%, P <0.001) and ACR70 (17% versus 3%, P =0.001).
They also showed more DAS remission (18% versus 7%,
P =0.017) and a larger increase in functional ability
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P <0.001). After three months, mean HAQ score was 0.59
in non-PP patients treated with initial combination ther-
apy and 0.92 in those treated with initial monotherapy
(see also Figure 2). In Table 2 the main results are summa-
rized. With regression analyses similar results were ob-
tained (data not shown).Clinical and radiographic outcomes after one year follow up
Following initial combination therapy, after one year, PP
patients more often achieved ACR20 response (93% ver-
sus 80%, P =0.026) and DAS remission (36% versus 21%,
P =0.034) than following initial monotherapy. Other
clinical outcomes were not significantly different after
one year between PP patients treated with initial com-
bination therapy or with initial monotherapy. Radio-
graphic damage progression after one year was lower in
PP patients treated with initial combination therapy than
those treated with initial monotherapy (median (IQR)
increase in SHS 0.0 (0.0 to 2.0) versus 1.5 (0.0 to 5.0),
P =0.001) and there were significantly fewer patients with
RRP (10% versus 26%, P =0.006).
After one year, more non-PP patients treated with initial
combination therapy also fulfilled the ACR20 response cri-
teria (85% versus 72%, P =0.024) and the ACR50 response
criteria (68% versus 52%, P =0.027) than non-PP patients
treated with initial monotherapy. Median (IQR) increase
in SHS was 0.0 (0.0 to 0.5) in non-PP patients treated with
initial combination therapy and 0.0 (0.0 to 1.0) in those
treated with initial monotherapy (P =0.451). RRP occurred
in 11% of non-PP patients treated with initial monother-
apy compared to 4% in those treated with initial com-
bination therapy (P =0.054). Table 2 shows a summary of
these results. With regression analyses similar results were
obtained (data not shown).
During the first year of follow up, the improvement in
HAQ score after initial combination therapy was similar
in PP and non-PP patients (P =0.795 after three months;
P =0.687 after one year) (Figure 2). There was less im-
provement in HAQ score after initial monotherapy,
again similarly in PP and non-PP patients (P =0.108 after
three months; P =0.967 after one year).Toxicity
To evaluate possible toxicity of overtreatment with ini-
tial combination therapy, the numbers of PP and non-PP
patients treated with initial combination therapy who re-
ported an AE and/or SAE were compared. Of 92 PP pa-
tients randomized to initial combination therapy, 31
(34%) reported at least one AE or SAE, compared to 58/
125 patients (46%) with a non-PP. Twenty-eight of 92
PP patients (30%) and 54/125 non-PP patients (43%) re-
ported one or more AE (P =0.066). Four PP patients(4%) and six non-PP patients (5%) reported one or more
SAE (P =1.000).
Discussion
The results of this post hoc analysis in the BeSt study
show that patients with recent-onset RA with a non-
poor prognosis and patients with a poor prognosis re-
spond similarly to the treatment strategy options. Both
groups benefit more from initial combination therapy
than from initial monotherapy and the success of a sec-
ond conventional DMARD after failing on the first is
limited in both groups.
Previous studies have shown that initial combination
therapy results in better clinical and radiographic out-
comes than initial monotherapy in patients with early RA
on a group level [1-5,7]. It was suggested in the 2010 rec-
ommendations for the management of RA [8] that pa-
tients with favourable prognostic factors at baseline do not
need initial combination therapy because they will re-
spond equally well to initial monotherapy and that pa-
tients with a poor prognosis would benefit more from
initial combination therapy. This was revoked in the 2013
update: it is now recommended that all patients should re-
ceive a similar initial treatment [9]. Still, the updated rec-
ommendations state that risk evaluation is an important
aspect in the therapeutic approach of RA, and that pa-
tients with a favourable prognosis would require a differ-
ent type of follow up treatment than patients with a poor
prognosis after failure on initial MTX monotherapy [9].
To test these recommendations, we classified patients
as having a poor prognosis (PP) or a non-poor prognosis
(non-PP), as a representative of the heterogeneous group
of patients ‘with a low risk of poor RA outcome’ men-
tioned in the updated 2013 recommendations, based on
well-known and frequently used risk factors [10-13]. We
tested whether these risk groups, over three-monthly
evaluations in the first year of the BeSt study, responded
differently to these treatments.
We found that in both PP and non-PP patients, initial
combination therapy is more effective, compared to
monotherapy, in inducing an early (that is, after three
months) decrease in disease activity and early improve-
ment in functional ability, this notwithstanding the fact
that after six months on MTX monotherapy signifi-
cantly more non-PP patients than PP patients achieved
a low DAS (64% versus 43%). The improvement in func-
tional capacity in patients treated with initial combin-
ation therapy was equal in PP and non-PP patients,
both after three months and after one year. This indi-
cates an early equal gain in functional capacity in both
prognosis categories. These differences in clinical out-
comes are explicit after three months, and remain, follow-
ing treat-to-target adjustments in therapy, only marginal
after one year.
Table 2 Main clinical and radiographic outcomes of poor and non-poor prognosis patients receiving initial monotherapy
or initial combination therapy after 3 months and after 1 year
Poor prognosis patients
Initial mono Initial combo P-value
DAS remission
After 3 months 5 (5) 15 (17) 0.016
After 1 year 21 (21) 31 (36) 0.034
ACR20 response
After 3 months 35 (38) 57 (70) < 0.001
After 1 year 73 (80) 75 (93) 0.026
ACR50 response
After 3 months 12 (13) 40 (48) <0.001
After 1 year 52 (57) 59 (71) 0.060
ACR70 response
After 3 months 4 (4) 20 (24) <0.001
After 1 year 28 (30) 35 (44) 0.081
Decrease in HAQ score, median (IQR)
After 3 months −0.38 (−0.63, 0.06) −0.75 (−1.13, −0.25) <0.001
After 1 year −0.75 (−1.13, −0.38) −0.88 (−1.38, −0.38) 0.110
SHS progression
After 1 year, median (IQR) 1.5 (0, 5.0) 0 (0, 2.0) 0.001
RRP 24 (26) 8 (10) 0.006
Non-poor prognosis patients
Initial mono Initial combo P-value
DAS remission
After 3 months 7 (7) 23 (18) 0.017
After 1 year 35 (36) 43 (36) 1.000
ACR20 response
After 3 months 38 (44) 79 (71) <0.001
After 1 year 63 (72) 96 (85) 0.024
ACR50 response
After 3 months 12 (13) 56 (49) <0.001
After 1 year 44 (52) 77 (68) 0.027
ACR70 response
After 3 months 3 (3) 20 (17) 0.001
After 1 year 29 (33) 45 (39) 0.380
Decrease in HAQ score, median (IQR)
After 3 months −0.38 (−0.75, 0) −0.63 (−1.13, −0.25) <0.001
After 1 year −0.63 (−1.13, −0.13) −0.88 (−1.25, −0.31) 0.040
SHS progression
After 1 year, median (IQR) 0 (0, 1.5) 0 (0, 1.0) 0.451
RRP 10 (11) 4 (4) 0.054
Numbers indicate number of patients (percentage) unless indicated otherwise. ACR response: according to the American College of Rheumatology criteria [17];
DAS remission, disease activity score <1.6 [16]; Initial combo: initial combination therapy with either prednisone or infliximab; Initial mono: initial monotherapy
with methotrexate; non-poor prognosis (presence of ≤2 of 4 poor prognostic factors); HAQ, health assessment questionnaire (scale 0 to 3); poor prognosis
(presence of ≥3 of 4 poor prognostic factors); SHS, Sharp van der Heijde score; RRP, rapid radiographic progression, defined as increase in Sharp van der Heijde
score ≥5 points during the first year.
Markusse et al. Arthritis Research & Therapy 2014, 16:430 Page 6 of 9
http://arthritis-research.com/content/16/5/430
Markusse et al. Arthritis Research & Therapy 2014, 16:430 Page 7 of 9
http://arthritis-research.com/content/16/5/430There was no difference among PP and non-PP pa-
tients in response to SSA as the second conventional
synthetic DMARD after failure to achieve a low DAS on
initial MTX monotherapy: similarly low percentages of
patients achieved a DAS ≤2.4 (21% of non-PP patients
and 28% of PP patients). This appears to be at odds with
recommendation 8 of the updated 2013 EULAR recom-
mendations for the management of RA [9].
Overall, as a consequence of the definition of poor or
non-poor prognosis, patients with a non-PP showed less
radiographic joint damage progression than patients
with a poor prognosis. After one year of targeted treat-
ment, significantly less radiographic joint damage pro-
gression occurred after initial combination therapy in PP
patients than after initial monotherapy. Thus it appears
that for radiographic damage progression indeed, as ori-
ginally formulated in the 2010 EULAR recommenda-
tions for the management of RA, PP patients ‘have more
to gainʼ from the initial treatment choice [8].
Our definition of poor or non-poor prognosis was based
on factors that are associated with (rapid) radiographic
progression and are also used in prediction models
[10-13]. However, early treatment initiation and targeted
therapy, including the option of biologic DMARDs, have
contributed to prevent this disease outcome in most BeSt
patients to date. As RRP nowadays can also be better pre-
vented with early effective treatment, models designed to
predict RRP perform moderately in clinical practice. In
addition, they do not provide information on clinical out-
comes. Of the patients defined as PP according to the
presence of ≥3 risk factors, only 26% actually developed
RRP when treated with initial monotherapy and 10% de-
veloped RRP when treated with initial combination ther-
apy. When PP is defined according to the matrix model of
Visser et al. [10], 46% and 12% developed RRP when
treated with initial monotherapy or combination therapy,
respectively (Additional file 2). Thus, despite familiarity
with prognostic factors, it is still difficult to predict the
prognosis.
Consequently, it is proper to evaluate the efficacy of the
initial treatment choice in terms of rapid relief of symp-
toms and functional improvement due to suppression of
inflammation. Our data show that initial combination ther-
apy is more successful in achieving these outcomes than
initial MTX monotherapy, both for PP patients and for
non-PP patients. In fact, clinical responses were very simi-
lar (and satisfactory) in all patients if they received initial
combination treatment. In addition, although maybe not
clinically relevant, PP patients showed less radiographic
damage progression after initial combination therapy than
after initial monotherapy. Also, more than half of the pa-
tients receiving initial combination therapy could discon-
tinue prednisone or infliximab due to low disease activity,
as soon as the protocol allowed drug discontinuation.There was no significant difference in the number of
AEs and SAEs reported by PP or non-PP patients on ini-
tial combination therapy. Similar toxicity among the four
treatment arms has already been reported [6,7]. Hence,
it appears that extra caution for the use of combination
therapy in either group is not warranted.Conclusion
The definition of non-poor or poor prognosis shows a
moderate performance in predicting radiographic progres-
sion, despite the use of two different methods and based
on risk factors in validated prediction models. Overall,
patients in the BeSt study benefitted from initial combin-
ation therapy with better clinical outcomes and more
functional improvement at three months than after initial
monotherapy, regardless of prognosis category. Response
to a second conventional synthetic DMARD after failure
on methotrexate monotherapy was similar in patients with
a poor or a non-poor prognostic profile, and generally dis-
appointing. These results suggest that prognostic factors
associated with future radiographic damage progression
contribute little to predict early clinical response to initial
treatment, and therefore, in our opinion tailored treatment
based on prognosis as suggested by the EULAR guidelines
is currently not feasible. The choice of treatment strategy
may depend less on these prognostic factors and more on
the estimated need for rapid relief of symptoms and limi-
tations due to active disease in our patients.Additional files
Additional file 1: Results. File contains data about risk stratification
based on the matrix model of Visser et al., on mean difference in health
assessment questionnaire (HAQ) score and toxicity.
Additional file 2: Table S1. File contains data about risk stratification
based on the matrix model of Visser et al., on clinical and radiographic
outcomes using the t-test and Fischer’s exact test.
Additional file 3: Table S2. File contains data about risk stratification
based on the matrix model of Visser et al., on clinical and radiographic
outcomes using regression analyses.
Additional file 4: Figure S1. File contains a figure showing the mean
difference in health assessment questionnaire (HAQ) score after risk
stratification based on the matrix model of Visser et al.Abbreviations
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